Form 6-K — CureVac N.V.: sales of common shares by members of its management team (December 14, 2022)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission, Commission File Number 001-39446. It states that on December 14, 2022 the company issued a press release announcing sales of its common shares by certain members of its management team, made solely to cover tax obligations in connection with the Virtual Stock Option Plan. The information is incorporated by reference into Form F-3, File No. 333-259613. The press release dated December 14, 2022 is listed as Exhibit 99.1.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: sales of common shares by members of its management team (December 14, 2022).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2022-12-14-0001104659-22-126983-4398f8aa46/
, SHA-256 0c472de3e136944307737b0d1067530177a5e8e0887668e49eb62ceb36197f8f.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On December 14, 2022, CureVac N.V. (the “Company”) issued a press release announcing sales of the Company's common shares by certain members of its management team, made solely to cover tax obligations in connection with the Virtual Stock Option Plan. The information included in this Form 6-K (including Exhibit 99.1) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: December 14, 2022 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated December 14, 2022.
File and source
- File
- SEC_CVAC_6-K_filed2022-12-14_0001104659-22-126983.htm
- Size
- 13,367 bytes
- SHA-256
- 0c472de3e136944307737b0d1067530177a5e8e0887668e49eb62ceb36197f8f
- Original
- www.sec.gov